MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, BJDX had -$1,360,808 decrease in cash & cash equivalents over the period. -$1,359,793 in free cash flow.

Cash Flow Overview

Change in Cash
-$1,360,808
Free Cash flow
-$1,359,793

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss
-1,597,632 -3,821,039
Depreciation expense
10,624 36,143
Stock-based compensation expense
183 -251
Amortization of right-of-use asset
21,000 54,105
Write-off and impairment of property and equipment
36,574 495
Deferred offering costs
101,170 0
Prepaid expenses and other current assets
-171,727 -291,460
Other non-current assets
-13,437 -13,093
Accounts payable
52,345 -36,305
Accrued expenses and other current liabilities
33,119 223,387
Non-cash interest expense for notes payable
0 0
Net cash used in operating activities
-1,359,793 -3,238,912
Proceeds from issuance of common stock and prefunded warrants
0 3,846,692
Issuance costs related to issuance of common stock
0 464,670
Payment of finance lease
1,015 1,979
Proceeds from issuance of notes payable, net of discounts of 287,580
0 0
Repayment of notes payable
0 0
Proceeds from exercise of class d warrants
0 -
Net cash provided by financing activities
-1,015 3,380,043
Purchase of property and equipment
0 0
Net cash used in investing activities
0 0
Increase in cash and cash equivalents
-1,360,808 141,131
Cash and cash equivalents at beginning of period
4,301,945 -
Cash and cash equivalents at end of period
3,082,268 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics, Inc. (BJDX)